Oncoinvent ASA (7BG)
XDUS
Closed
Oct 7, 2026
Day's Range
6.9852 wk Range
1.79Overview - 7BG - Oncoinvent ASA
Key Statistics
Valuation
Enterprise Value
-169.90M
P/E (Trailing)
‪-0.06‬
Price / Book
‪0.05‬
EV / EBITDA
‪1.39‬
Profitability
Operating Margin
‪-673.03%‬
Return on Assets
‪-75.65%‬
Return on Equity
‪-105.97%‬
Ownership
Shares Outstanding
4.47M
Price stats
50-Day Avg
‪8.51‬
200-Day Avg
‪4.56‬
Peers - 7BG - Oncoinvent ASA
Peer Comparison
Compared with companies in Biotechnology listed on XDUS.
- 7BGXDUSOncoinvent ASA+76.57%52-week change-0.06P/E (Trailing)—Profit Margin
- 0QFXDUSModerna Inc.+85.69%52-week change—P/E (Trailing)—Profit Margin
- 2LBXDUSIovance Biotherapeutics Inc.+83.47%52-week change-10.55P/E (Trailing)‪34.27%‬Profit Margin
- 3920XDUSSpyre Therapeutics, Inc.+82.13%52-week change-37.88P/E (Trailing)—Profit Margin
- 0MEXDUSTwist Bioscience Corporation+80.08%52-week change-108.42P/E (Trailing)‪50.72%‬Profit Margin
- 42ZXDUSRevolution Medicines, Inc.+78.13%52-week change-30.44P/E (Trailing)—Profit Margin
- 3O8XDUSOmeros Corp.+77.85%52-week change-333.00P/E (Trailing)—Profit Margin
Profile Summary - 7BG - Oncoinvent ASA
About
Oncoinvent ASA is a Norwegian clinical-stage biotechnology company focused on developing radiopharmaceutical therapies for cancer treatment. Its lead product candidate, Radspherin, is an investigational alpha-radiation therapy using calcium carbonate microparticles loaded with the radionuclide radium-224. Designed for…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
